Aerie Pharmaceuticals to Participate in Two Investor Conferences in December

IRVINE, Calif.–(BUSINESS WIRE)– Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class glaucoma therapies, today announced
that company management will participate in the following conferences in
December.

• Citi 2016 Global Healthcare Conference
  • Attendee: Richard Rubino, Chief Financial Officer
  • Date: Thursday, December 8, 2016
  • Location: New York, NY
• BMO Capital Markets 2016 Prescription for Success Healthcare Conference
  • Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive
    Officer
  • Presentation Date: Wednesday, December 14, 2016
  • Presentation Time: 5:00pm E.T.
  • Location: New York, NY

The BMO Capital Markets 2016 Prescription for Success Healthcare
Conference fireside chat discussion will be webcast live and may be
accessed by visiting Aerie’s website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie’s two lead product candidates are once-daily IOP-lowering
therapies with novel mechanisms of action to treat patients with
glaucoma or ocular hypertension. The NDA filing for
Rhopressa™ (netarsudil ophthalmic solution) 0.02% was originally
submitted in the third quarter of 2016 and is expected to be resubmitted
in January 2017. The second product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,
which is a fixed dose combination of Rhopressa™ and widely
prescribed PGA latanoprost, currently has two Phase 3 registration
trials underway, named Mercury 1 and Mercury 2. If these trials are
successful, a Roclatan™ NDA filing is expected to take place near
year-end 2017. Aerie is also focused on the development of additional
product candidates and technologies in ophthalmology.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201005128/en/